Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 26

Sort by

Sort Order Select

Journal Articles

First-in-Human, Phase Ia , Dose Escalation, Monotherapy Study of QLS32015, a Novel GPRC5D×CD3 T-Cell Engaging Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Lu-Gui Qiu, Gang An, Baijun Fang, Xiaobing Huang, Yan Xu, Yuzhang Liu, Feifei Che, Xinai Yang, Xianlin Duan, Peng Shao, Xiaoyan Kang

Blood (2024) 144 (Supplement 1): 1990.

https://doi.org/10.1182/blood-2024-201960

Published: 2024

Journal Articles

Anti-CD3/B-Cell Maturation Antigen Bispecific Antibody CM336 in Relapsed/Refractory Multiple Myeloma: An Open-Label, Phase I/II Study

Gang An, Zhongxia Huang, Aibin Liang, Baijun Fang, Hongmei Jing, Lu-Gui Qiu

Blood (2024) 144 (Supplement 1): 3377.

https://doi.org/10.1182/blood-2024-206742

Published: 2024

Journal Articles

Subgroup Analyses of Phase 2 Study: Evaluating the Efficacy of Fully Human BCMA-Targeting CAR T Cells (Zevorcabtagene Autoleucel) in Patients with Relapsed/Refractory Multiple Myeloma

Blood (2024) 144 (Supplement 1): 4762.

https://doi.org/10.1182/blood-2024-204620

Published: 2024

Journal Articles

Impact of CAR T-Cell Persistence on Clinical Outcomes in Relapsed/Refractory Multiple Myeloma: Insights from the Phase 2 Fumanba-1 Study

Chunrui Li, Dehui Zou, Di Wang, Baijun Fang, He Huang, Jianyong Li, Bing Chen, Jing Liu, Xi Zhang, Yujun Dong, Kai Hu, Peng Liu, Jianqing Mi, Kaiyang Ding, Zhenyu Li, Qie Dong, Fuyuan Zhang, Guang Hu, Lu-Gui Qiu

Blood (2024) 144 (Supplement 1): 4761.

https://doi.org/10.1182/blood-2024-204355

Published: 2024

Journal Articles

Weekly Selinexor, Bortizomib and Dexamethasone (SVd) Versus Twice Weekly Bortizomib and Dexamethasone (Vd) in Chinese Patients with Relapsed and Refractory Multiple Myeloma (RRMM): Primary Analysis of Phase 3 Bench Study

Blood (2024) 144 (Supplement 1): 4748.

https://doi.org/10.1182/blood-2024-202893

Published: 2024

Journal Articles

Real-World Clinical Outcomes of Daratumumab-Based Regimens in Chinese Patients with Multiple Myeloma By Cytogenetic Risk: A Subgroup Analysis of the MMY4032 Study

Luqun Wang, Wei Yang, Ting Niu, Yafei Wang, Rong Fu, Yuping Zhong, Kaiyang Ding, Kai Sun, Baijun Fang, Hong Liu, Wenbin Qian, Hui Liu, Yanhui Li, Yishen Yang, Jianmin Zhuo, Xi Chen, Canchan Cui, Jin Lu

Blood (2024) 144 (Supplement 1): 7874.

https://doi.org/10.1182/blood-2024-201134

Published: 2024

Journal Articles

Ixazomib Based Regimens As Front-Line Treatment in Newly Diagnosed Multiple Myeloma Patients in China: A Real-World Data from Infinite Study

Fu Cheng Cheng, Song Jin, Junling Zhuang, Xin Zhou, Fan Zhou, Yuhua Li, Kaiyang Ding, Ting Niu, Wenming Chen, Baijun Fang, Li-Li Chen, Rong Fu, Hao Zhang, Jiaping Fu, Xiuju Wang, Sha Liu, Lin Li, Depei Wu

Blood (2024) 144 (Supplement 1): 6970.

https://doi.org/10.1182/blood-2024-204366

Published: 2024

Journal Articles

Efficacy and Safety of Carfilzomib-Based Regimens in Multiple Myeloma: Single-Center Real-World Experience

Yaomei Wang, Xueting Wang, Yuzhang Liu, Lijie Liang, Lina Liu, Wenyi Lu, Yongping Song, Baijun Fang

Blood (2024) 144 (Supplement 1): 7836.

https://doi.org/10.1182/blood-2024-206491

Published: 2024

Journal Articles

The Diversity of FLT3-ITD and the Prognostic Impact in Adult Acute Myeloid Leukemia

Jingyi Yang, Shanlan Mo, Xudong Wei, Xiaodong Lv, Baijun Fang, Yanli Zhang, Jian Zhou, Hu Zhou, Yuewen Fu, Quande Lin, Delong Liu, Yongping Song, Qianfei Wang, Keshu Zhou

Blood (2023) 142 (Supplement 1): 5756.

https://doi.org/10.1182/blood-2023-178989

Published: 2023

Journal Articles

Interim Results of the Launch Study-a Multicenter, Open-Label Study of Selinexor, Dexamethasone and Chemotherapy Drugs in Relapsed/ Refractory Multiple Myeloma

Chunyan Sun, Baijun Fang, Guangxun Gao, Fuling Zhou, Aili He, Fei Zhao, Junying Li, Chun Zhang, Li Weiming, Hui Cheng, Huili Cai, Bin Chen, Jingming Guo, Yu Hu

Blood (2023) 142 (Supplement 1): 4763.

https://doi.org/10.1182/blood-2023-186220

Published: 2023

Journal Articles

Heritable SETBP1 Mutations Associated with Myelodysplastic Syndrome and Acute Myeloid Leukemia

Jingyi Yang, Shanlan Mo, Xudong Wei, Xiaodong Lv, Ya Zhang, Yuewen Fu, Baijun Fang, Yanli Zhang, Jian Zhou, Hu Zhou, Quande Lin, Delong Liu, Yongping Song, Qianfei Wang, Keshu Zhou

Blood (2023) 142 (Supplement 1): 5684.

https://doi.org/10.1182/blood-2023-182788

Published: 2023

Journal Articles

Real-World Analysis of Treatment Patterns and the Effectiveness and Safety Profile of Daratumumab-Based Regimens in Chinese Patients with Newly Diagnosed or Relapsed/Refractory Multiple Myeloma

Luqun Wang, Wei Yang, Yafei Wang, Ting Niu, Rong Fu, Yuping Zhong, Wenbin Qian, Kaiyang Ding, Kai Sun, Hong Liu, Baijun Fang, Hui Liu, Yanhui Li, Yishen Yang, Jianmin Zhuo, Xi Chen, Canchan Cui, Jin Lu

Blood (2023) 142 (Supplement 1): 6635.

https://doi.org/10.1182/blood-2023-180948

Published: 2023

Journal Articles

Characteristics and Safety Profile in Patient Received Ixazomib in China: Interim Analysis of a National, Prospective, Non-Interventional Study of Using Ixazomib in Real-World Clinical Practice (INFINITE Study)

Chengcheng Fu, Xin Zhou, Junling Zhuang, Fan Zhou, Yuhua Li, Wenming Chen, Rong Fu, Baijun Fang, Ting Niu, Hao Zhang, Lin Li, Depei Wu

Blood (2022) 140 (Supplement 1): 12642–12644.

https://doi.org/10.1182/blood-2022-165127

Published: 2022

Journal Articles

Phase I Study of a Novel Oral Proteasome Inhibitor TQB3602 in Relapsed/Refractory Multiple Myeloma

Wenjiao Tang, Yan Li, Qiushi Liang, Ying Qu, Li Zhang, Yuzhang Liu, Baijun Fang, Zeng Yun, Xiaobo Du, Yaming Xi, Ting Wang, Xin Li, Jie Huang, Wenbin Qian, Zhen Cai, Qingwei Zhao, Yue Lv, Ting Niu

Blood (2022) 140 (Supplement 1): 4396–4397.

https://doi.org/10.1182/blood-2022-168091

Published: 2022

Journal Articles

Phase Ⅱ Study of Fully Human BCMA-Targeting CAR-T Cells (Zevorcabtagene Autoleucel) in Patients with Relapsed/Refractory Multiple Myeloma

Blood (2022) 140 (Supplement 1): 4564–4565.

https://doi.org/10.1182/blood-2022-168610

Published: 2022

Journal Articles

Updated Results of Fumanba-1: A Phase 1b/2 Study of a Novel Fully Human B-Cell Maturation Antigen-Specific CAR T Cells (CT103A) in Patients with Relapsed and/or Refractory Multiple Myeloma

Blood (2022) 140 (Supplement 1): 7435–7436.

https://doi.org/10.1182/blood-2022-166465

Published: 2022

Journal Articles

Phase 2 March Study: ATG-010 Plus Low Dose Dexamethasone in Chinese Relapsed/Refractory Multiple Myeloma (RRMM) Patients Previously Treated with an Immunomodulatory Agent (IMiD) and a Proteasome Inhibitor (PI)

Blood (2021) 138 (Supplement 1): 4770.

https://doi.org/10.1182/blood-2021-145282

Published: 2021

Journal Articles

ATG-010 Plus Low-Dose Dexamethasone (Sd) in Chinese Relapsed/Refractory Multiple Myeloma (RRMM) Patients Previously Received Chimeric Antigen Receptor T-Cell (CAR-T)

Blood (2021) 138 (Supplement 1): 4778.

https://doi.org/10.1182/blood-2021-146784

Published: 2021

Journal Articles

Autologous Hematopoietic Stem Cell Infusion for Myelosuppression after Bcma-CART Therapy in Relapsed Myeloma Patients

Quande Lin, PhD, Lu Han, MS, Jian Zhou, MD PhD, Lina Liu, Master, Yuzhang Liu, master, Fengkuan Yu, Master, YangLi Zhang, Master, Wenli Zuo, Doctor, Keshu Zhou, MD, Baijun Fang, MD, Quanli Gao, Doctor, Xudong Wei, PhD, Delong Liu, MD PhD, Yongping Song, MD PhD

Blood (2019) 134 (Supplement_1): 1851.

https://doi.org/10.1182/blood-2019-128410

Published: 2019

Journal Articles

Treatment of Epstein-Barr Virus Associated Central Nervous System Diseases after Allogeneic Hematopoietic Stem Cell Transplantation with Intrathecal Donor Lymphocyte Infusion

Juanjuan Zhao, Yingling Zu, Lu Han, Yanli Zhang, Ruirui Gui, Fengkuan Yu, Zhen Li, Huifang Zhao, Baijun Fang, MD, Quande Lin, Yongping Song, MD, Delong Liu, MD PhD, Jian Zhou, MD PhD

Blood (2018) 132 (Supplement 1): 5685.

https://doi.org/10.1182/blood-2018-99-115742

Published: 2018

NARROW

First-in-Human, Phase Ia , Dose Escalation, Monotherapy Study of QLS32015, a Novel GPRC5D×CD3 T-Cell Engaging Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Anti-CD3/B-Cell Maturation Antigen Bispecific Antibody CM336 in Relapsed/Refractory Multiple Myeloma: An Open-Label, Phase I/II Study

Subgroup Analyses of Phase 2 Study: Evaluating the Efficacy of Fully Human BCMA-Targeting CAR T Cells (Zevorcabtagene Autoleucel) in Patients with Relapsed/Refractory Multiple Myeloma

Impact of CAR T-Cell Persistence on Clinical Outcomes in Relapsed/Refractory Multiple Myeloma: Insights from the Phase 2 Fumanba-1 Study

Weekly Selinexor, Bortizomib and Dexamethasone (SVd) Versus Twice Weekly Bortizomib and Dexamethasone (Vd) in Chinese Patients with Relapsed and Refractory Multiple Myeloma (RRMM): Primary Analysis of Phase 3 Bench Study

Real-World Clinical Outcomes of Daratumumab-Based Regimens in Chinese Patients with Multiple Myeloma By Cytogenetic Risk: A Subgroup Analysis of the MMY4032 Study

Ixazomib Based Regimens As Front-Line Treatment in Newly Diagnosed Multiple Myeloma Patients in China: A Real-World Data from Infinite Study

Efficacy and Safety of Carfilzomib-Based Regimens in Multiple Myeloma: Single-Center Real-World Experience

The Diversity of FLT3-ITD and the Prognostic Impact in Adult Acute Myeloid Leukemia

Interim Results of the Launch Study-a Multicenter, Open-Label Study of Selinexor, Dexamethasone and Chemotherapy Drugs in Relapsed/ Refractory Multiple Myeloma

Heritable SETBP1 Mutations Associated with Myelodysplastic Syndrome and Acute Myeloid Leukemia

Real-World Analysis of Treatment Patterns and the Effectiveness and Safety Profile of Daratumumab-Based Regimens in Chinese Patients with Newly Diagnosed or Relapsed/Refractory Multiple Myeloma

Characteristics and Safety Profile in Patient Received Ixazomib in China: Interim Analysis of a National, Prospective, Non-Interventional Study of Using Ixazomib in Real-World Clinical Practice (INFINITE Study)

Phase I Study of a Novel Oral Proteasome Inhibitor TQB3602 in Relapsed/Refractory Multiple Myeloma

Phase Ⅱ Study of Fully Human BCMA-Targeting CAR-T Cells (Zevorcabtagene Autoleucel) in Patients with Relapsed/Refractory Multiple Myeloma

Updated Results of Fumanba-1: A Phase 1b/2 Study of a Novel Fully Human B-Cell Maturation Antigen-Specific CAR T Cells (CT103A) in Patients with Relapsed and/or Refractory Multiple Myeloma

Phase 2 March Study: ATG-010 Plus Low Dose Dexamethasone in Chinese Relapsed/Refractory Multiple Myeloma (RRMM) Patients Previously Treated with an Immunomodulatory Agent (IMiD) and a Proteasome Inhibitor (PI)

ATG-010 Plus Low-Dose Dexamethasone (Sd) in Chinese Relapsed/Refractory Multiple Myeloma (RRMM) Patients Previously Received Chimeric Antigen Receptor T-Cell (CAR-T)

Autologous Hematopoietic Stem Cell Infusion for Myelosuppression after Bcma-CART Therapy in Relapsed Myeloma Patients

Treatment of Epstein-Barr Virus Associated Central Nervous System Diseases after Allogeneic Hematopoietic Stem Cell Transplantation with Intrathecal Donor Lymphocyte Infusion

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only